IAXO-102

Gefahreninformationscode (GHS)

• Bildanzeige (GHS)

  

• Alarmwort

  Warnung

• Gefahrenhinweise

  H302：Gesundheitsschädlich bei Verschlucken.

  H315：Verursacht Hautreizungen.

  H319：Verursacht schwere Augenreizung.

  H335：Kann die Atemwege reizen.

• Sicherheit

  P261：Einatmen von Staub vermeiden.

  P305+P351+P338：BEI KONTAKT MIT DEN AUGEN: Einige Minuten lang behutsam mit Wasser spülen. Eventuell vorhandene Kontaktlinsen nach Möglichkeit entfernen. Weiter spülen.

IAXO-102 Chemische Eigenschaften,Einsatz,Produktion Methoden

• Biologische Aktivität

  IAXO-102 is a TLR4 antagonist targeting the MD-2 and CD14 co-receptors,which inhibits MAPK and p65 NF-κB phosphorylation and downregulates the expression of TLR4-dependent pro-inflammatory proteins. It inhibits the development of experimental abdominal aortic aneurysm (AAA).

• in vitro

  IAXO-102 (1-10 μM, for 2 hours) inhibits MAPK and p65 NF-κB phosphorylation in human umbilical vein endothelial (HUVEC) cells.
  IAXO-102 (10 μM, for 17 hours) suppresses LPS induced proinflammatory proteins MCP-1 and IL-8 production in HUVEC.

  Western Blot Analysis

  Cell Line:	Human umbilical vein endothelial (HUVEC) cells
  Concentration:	1-10 μM
  Incubation Time:	Pretreatment for 1 hour and then exposed to LPS (100 ng/mL) for additional 1 hour
  Result:	Significantly inhibited LPS- stimulated MAPK/p65nF-ΚB phosphorylation.

• in vivo

  IAXO-102 (3 mg/kg/day, sc for 28 days) significantly retards Angiotensin II induced increase in aortic diameter in mice.

  Animal Model: < /td>	Six-monthold ApoE ?/? /C57Bl6
  Dosage:	3 mg/kg/day
  Administration:	SC for 28 days
  Result:	Significantly retarded Angiotensin II -induced increase in aortic diameter.

• target

  Target	Value
  TLR4 ()
  MAPK ()
  NF-κB ()

IAXO-102 Anbieter Lieferant Produzent Hersteller Vertrieb Händler.

Global(26)Suppliers